

Screening and efficacy tests on *in vitro* Hepa-RG® models


✓ Screening your drugs in a fast and cost-effective *in vitro* healthy and steatosis HepaRG® model.

Key benefits

Get benefits from our HepaRG® *in vitro* model: quickly assess the effects of your compounds on cell viability/function, and hepatic lipid accumulation in a simple HepaRG culture system.

In vitro MODEL

- **Cell line:** HepaRG® (Biopredic)
 - **Healthy model:** mature HepaRG in physiological medium
 - **Steatosis model:** 7-day oleic acid loaded / mature HepaRG
- Experimental design:**




Less than 1 month for a study report



In vitro HepaRG® model

ACETAMINOPHEN (APAP) REDUCES CELL VIABILITY AND ALBUMIN SECRETION, WHILE FXR AGONIST OBETICHOLIC ACID (OCA) IS NEUTRAL




(A) LDH release (cell viability) and (B) albumin secretion (cell function)

*p<0.05 and ££p<0,01 vs. control medium.


In vitro HepaRG® steatosis model

OLEIC ACID LOADING STRONGLY INCREASES INTRACELLULAR LIPID ACCUMULATION AND REDUCES CELL VIABILITY VIA LIPOTOXICITY



(A) Lipid accumulation (Oil Red O staining per viable cell) and (B) cell viability (LDH release). \$ p<0.05 vs. control medium.

PHARMACOLOGICAL VALIDATION: ACC INHIBITOR FIRSOCOSTAT MARKEDLY REDUCES INTRACELLULAR LIPID ACCUMULATION.



(A) Intracellular lipid accumulation (oil red O staining), (B) cell function (albumin secretion) and (C) cell viability (LDH release). \$p<0.05 vs. OA+DMSO